# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000886163-17-000048
Filing Date
2017-04-14
Accepted
2017-04-14 09:22:32
Documents
5
Effectiveness Date
2017-04-14

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | proxynotice.htm | DEFA14A | 18748
2 |  | a02ke5cligandpharmaceuti001.jpg | GRAPHIC | 235727
3 |  | a02ke5cligandpharmaceuti002.jpg | GRAPHIC | 105130
4 |  | a02ke7bligandpharmaceuti001.jpg | GRAPHIC | 206341
5 |  | a02ke7bligandpharmaceuti002.jpg | GRAPHIC | 172051
| Complete submission text file | 0000886163-17-000048.txt |  | 997780

Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

EIN.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-33093 | Film No.: 17762235
SIC: 2834 Pharmaceutical Preparations